OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Cancer is 103. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Correction to: The function and mechanisms of action of circular RNAs in Urologic Cancer	1703
Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance	912
SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers	891
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments	783
Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy	752
E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer	675
Spatial and functional dissection of cancer-associated fibroblasts-mediated immune modulation in H. pylori-associated gastric cancer	586
LMTK3 regulation of EV biogenesis and cargo sorting promotes tumour growth by reducing monocyte infiltration and driving pro-tumourigenic macrophage polarisation in breast cancer	566
Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment	540
Correction: m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC	474
KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers	398
Retraction Note: Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance	391
BRD9-p53-E2F1 circuit orchestrates cell growth and DNA damage repair in gastric cancer	376
The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer	355
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells	328
Immunotherapies in rare cancers	305
Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma	305
The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers	295
Exosomal circSIPA1L3-mediated intercellular communication contributes to glucose metabolic reprogramming and progression of triple negative breast cancer	284
The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis	278
The puppet master in the breast cancer “microecological community”: spatial and metabolic regulation of macrophage heterogeneity	272
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers	260
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery	246
LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling	243
TGF-β signaling promotes cervical cancer metastasis via CDR1as	242

Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers	232
Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives	231
Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications	226
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression	220
circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis	217
Development and validation of a small extracellular vesicle-derived RNA signature for early diagnosis of lung adenocarcinoma and prognosis in advanced stages	210
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway	209
ERK mediates interferon gamma-induced melanoma cell death	201
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research	200
Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis	200
Increased plasma concentrations of acyl-coenzyme A binding protein (ACBP) predict future lung cancer development in smokers at risk of cardiovascular disease	199
LncRNA PVT1 in human cancers: genomic complexity, isoforms, functional elements, mechanism of action, subcellular localization and possible role as a therapeutic target	196
Myofibroblast-derived extracellular vesicles facilitate cancer stemness of hepatocellular carcinoma via transferring ITGA5 to tumor cells	194
PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN	193
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection	193
Emerging roles of tRNA-derived fragments in cancer	189
Nanotechnology-leveraged CRISPR/Cas systems: icebreaking in trace cancer-related nucleic acids biosensing	188
Gold nanoparticles and gold nanorods in the landscape of cancer therapy	182
Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	181
Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis	181
Biomarker-empowered precision navigation of CAR-T cell therapy	179
Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities	178
Context-dependent effect of glucocorticoid receptor activity shapes ovarian cancer cell plasticity and therapy response	176
Nuclear receptors as novel regulators that modulate cancer radiosensitivity and normal tissue radiotoxicity	175
Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-κB p65 nuclear translocation	173
Bidirectional role of neutrophils in tumor development	172
Biofilm formation by the host microbiota: a protective shield against immunity and its implication in cancer	170
Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy	166
Efferocytosis: the art of cellular clearance and novel perspectives in disease therapy	161
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments	160
Effects of RNA methylation on Tumor angiogenesis and cancer progression	157
Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer	155
NK cells are never alone: crosstalk and communication in tumour microenvironments	153
LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling	149
Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside	148
Correction: The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC	148
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes	148
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state	148
Correction: Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1	147
Correction: CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	146
Retraction Note: Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis	146
Correction: Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis	146
Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition	145
Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance	144
Loss of TACC2 impairs chemokine CCL3 and CCL4 expression and reduces response to anti-PD-1 therapy in soft tissue sarcoma	144
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy	143
Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression	140
Circular RNA circCLASP2 promotes nasopharyngeal carcinoma progression through binding to DHX9 to enhance PCMT1 translation	139
Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment	138
The application of organoids in treatment decision-making for digestive system cancers: progress and challenges	137

Modeling pediatric low-grade glioma heterogeneity using human forebrain organoids	132
m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma	132
Context-dependent impact of type I interferon signaling in cancer	129
lncRNAs: the unexpected link between protein synthesis and cancer adaptation	129
A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression	128
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer	126
Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells	125
Targeting cholesterol-driven immunometabolism in cancer: from molecular circuits to clinical translation	124
Metabolic reprogramming and molecular crosstalk at the cancer–endothelial interface in ovarian carcinoma	122
Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy	122
EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?	120
Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis	119
CircAKT3 promotes prostate cancer proliferation and metastasis by enhancing the binding of RPS27A and RPL11	117
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies	116
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer	114
Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy	114
Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment	113
Molecular mechanisms of tumor resistance to radiotherapy	113
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors	112
Activation-induced cytidine deaminase causes recurrent splicing mutations in diffuse large B-cell lymphoma	112
Precision immunotherapy for head and neck cancer: therapeutic combinations, biomarker strategies, and translational challenges	111
Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK/mTOR pathway	111
CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	110
CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma	110
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response	108
Correction: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer	106
Correction: Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy	106
A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions	103